Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) Net Income towards Common Stockholders: 2013-2025

Historic Net Income towards Common Stockholders for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to $3.6 million.

  • Theravance Biopharma's Net Income towards Common Stockholders rose 128.47% to $3.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $21.8 million, marking a year-over-year increase of 144.15%. This contributed to the annual value of -$64.0 million for FY2024, which is 15.94% down from last year.
  • Theravance Biopharma's Net Income towards Common Stockholders amounted to $3.6 million in Q3 2025, which was down 93.41% from $54.8 million recorded in Q2 2025.
  • In the past 5 years, Theravance Biopharma's Net Income towards Common Stockholders ranged from a high of $927.1 million in Q3 2022 and a low of -$23.1 million during Q4 2024.
  • Moreover, its 3-year median value for Net Income towards Common Stockholders was -$12.7 million (2024), whereas its average is -$6.8 million.
  • Per our database at Business Quant, Theravance Biopharma's Net Income towards Common Stockholders skyrocketed by 4,400.00% in 2022 and then crashed by 318.54% in 2023.
  • Theravance Biopharma's Net Income towards Common Stockholders (Quarterly) stood at $25.8 million in 2021, then plummeted by 84.90% to $3.9 million in 2022, then crashed by 318.54% to -$8.5 million in 2023, then tumbled by 171.45% to -$23.1 million in 2024, then soared by 128.47% to $3.6 million in 2025.
  • Its last three reported values are $3.6 million in Q3 2025, $54.8 million for Q2 2025, and -$13.5 million during Q1 2025.